Top Markets
#1 Ontology Gas Ontology Gas +23.38%
#2 EXOD EXOD +22.08%
#3 Status Status +20.38%
#4 ETHGas ETHGas +14.18%
#5 aelf aelf +13.27%
#6 Fake World Assets Fake World Assets +10.63%
#7 The Black Bull The Black Bull +10.03%
#8 Derive Derive +8.64%
#9 Gas Gas +7.44%
#10 Meteora Meteora +6.38%
Coin of the day
Ontology Gas Ontology Gas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Clasificación en acciones #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Precio por acción
$9.81
Última sincronización: 2025-03-18
Capitalización bursátil
$48.68M
Cambio (1 día)
1.55%
Cambio (1 año)
0.00%
País
US
Comercio AlloVir, Inc. (ALVR)

Categoría

Healthcare
Ratio P/S de AlloVir, Inc. (ALVR)
Ratio P/S al August 2026 TTM: 0.00
Según los informes financieros más recientes y el precio de las acciones de AlloVir, Inc., el ratio P/S actual (TTM) es 0.00. Al final de 2023, el ratio P/S era 0.00.
Historial del ratio P/S de AlloVir, Inc. desde 2022 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US